Juvenile Idiopathic Arthritis Clinical Trial
— THE_JIAOfficial title:
Effectiveness and Feasibility of a Technology-supported Home-based Exercise Program for Adolescents With Juvenile Idiopathic Arthritis (THE_JIA Study): a Randomized Controlled Trial.
This study will aim to test the effectiveness and feasibility of a technology-supported home-based exercise program in adolescents with JIA. For this, adolescents (< 18 years) with JIA will be randomized to a 12-weeks home-based exercise program or usual care (i.e., no exercise control intervention). The home-based exercise intervention will be delivered remotely using a video calling app, and participants will be instructed to perform 3 sessions of weight-bearing exercise per week. Participants will be supported by educational materials, a heart rate monitor, and through periodic contact with an exercise specialist via video and phone calls, and text messages. The study's primary outcomes will be: cardiac and vascular function and structure using ultrasound imaging, body composition (DXA), aerobic capacity, muscle strength and functional capacity. In addition to that, the feasibility, safety, acceptability, and barriers and facilitators to the intervention will also be assessed.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | April 2024 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 18 Years |
Eligibility | Inclusion Criteria: - Patients with polyarticular or oligoarticular subtypes of juvenile idiopathic arthritis. Exclusion Criteria: - Cardiovascular, metabolic, pulmonary or renal diseases - Untreat thyroid disease - Blood pressure > 140/80 mmHg - Use of statin - Use of tobacco - Any other disease or condition that may prevent the practice of physical activity |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital das Clínicas da Faculdade de Medicina da USP - HCFMUSP | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endothelial function | Endothelial function will be assessed through the evaluation of brachial flow-mediated dilation using a vascular ultrasound. | Change from baseline to 12 weeks | |
Primary | Cardiac chamber dimensions (left ventricle diastolic and systolic diameters, interventricular septum, left ventricular posterior wall) | Left ventricle diastolic and systolic diameters, interventricular septum, and left ventricular posterior wall in millimeters per meter squared will be assessed using standard echocardiography. | Change from baseline to 12 weeks | |
Primary | Left ventricular ejection fraction (LVEF) | Left ventricular ejection fraction (LVEF) in percentage will be assessed using standard echocardiography. | Change from baseline to 12 weeks | |
Primary | Left ventricular mass index | The left ventricular mass index in grams per body surface area will be assessed using standard echocardiography. | Change from baseline to 12 weeks | |
Primary | Left ventricular diastolic function | Left ventricular diastolic function will be assessed using tissue Doppler-based measurements of transmitral E and A velocities in metre per second. | Change from baseline to 12 weeks | |
Primary | Myocardial deformation | Myocardial deformation in longitudinal, radial, and circumferential directions will be assessed using two-dimensional speckle-tracking (2DST) echocardiography and expressed as a percentage. | Change from baseline to 12 weeks | |
Primary | Body fat | Body fat in % will be assessed using dual-energy X-ray absorptiometry. | Change from baseline to 12 weeks | |
Primary | Lean mass | Lean mass in kilograms will be assessed using dual-energy X-ray absorptiometry. | Change from baseline to 12 weeks | |
Primary | Bone mineral content | Bone mineral content in grams will be assessed using dual-energy X-ray absorptiometry. | Change from baseline to 12 weeks | |
Primary | Aerobic fitness | Aerobic fitness will be assessed through a graded treadmill exercise test. VO2max will be assessed using a metabolic cart and expressed in millilitres per kilograms of body weight. | Change from baseline to 12 weeks | |
Primary | Vascular structure | Vascular structure will be assessed through the analysis of common carotid intima-media thickness using a vascular ultrasound. | Change from baseline to 12 weeks | |
Primary | Feasibility of the intervention | Feasibility of the intervention will be assessed through interviews investigating the experiences of the participants during the intervention. | Change from baseline to 12 weeks | |
Primary | Adherence to the intervention | The adherence to the intervention will be assessed using the data from the physical activity diaries and heart rate monitor and will be expressed as percentage of complete sessions. | Change from baseline to 12 weeks | |
Secondary | Disease activity | Participants' disease activity will be calculated using the Juvenile Arthritis Disease Activity Score. | Change from baseline to 12 weeks | |
Secondary | Disease activity | Participants' disease activity will be calculated using the Juvenile Arthritis Disease Activity Score. | Change from baseline to 24 weeks | |
Secondary | Functional ability | The functional ability of the participants with JIA will be assessed through the Brazilian-Portuguese version of the Childhood Health Assessment Questionnaire (CHAQ). | Change from baseline to 12 weeks | |
Secondary | Functional ability | The functional ability of the participants with JIA will be assessed through the Brazilian-Portuguese version of the Childhood Health Assessment Questionnaire (CHAQ). | Change from baseline to 24 weeks | |
Secondary | Health-related quality of life | Health-related quality of life will be assessed through the Pediatric Quality of Life Inventory (PedsQL). | Change from baseline to 12 weeks | |
Secondary | Health-related quality of life | Health-related quality of life will be assessed through the Pediatric Quality of Life Inventory (PedsQL). | Change from baseline to 24 weeks | |
Secondary | Cardiometabolic blood markers | The following cardiometabolic markers from blood will be assessed after 12-h fasting: blood glucose and insulin, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, and triglycerides. This data will be expressed in milligrams per deciliter. | Change from baseline to 12 weeks | |
Secondary | C-reactive protein | C-reactive protein levels in the blood will be assessed after 12-h fasting and expressed as milligrams per litre. | Change from baseline to 12 weeks | |
Secondary | Physical activity and sedentary behavior | Physical activity and sedentary behavior will be assessed using a thigh-worn accelerometer (activPAL). | Change from baseline to 12 weeks | |
Secondary | Physical activity and sedentary behavior | Physical activity and sedentary behavior will be assessed using a thigh-worn accelerometer (activPAL). | Change from baseline to 24 weeks | |
Secondary | Motivation to physical activity | Motivation to physical activity will be assessed using the Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2). | Change from baseline to 12 weeks | |
Secondary | Physical activity-related behavior | Physical activity-related behavior will be asseessed using the Stages of Change model. | Change from baseline to 12 weeks | |
Secondary | Food consumption | Food consumption will be assessed through 24-hour food recalls, collected on three non-consecutive days (one weekend day). | Change from baseline to 12 weeks | |
Secondary | Blood pressure | Blood pressure (arterial pressure) will be assessed non-invasively using a multi-parameter monitor. | Change from baseline to 12 weeks | |
Secondary | Cardiac autonomic function | Cardiac autonomic function will be assessed through the analysis of heart rate variability, which will be recorded using a heart rate monitor. | Change from baseline to 12 weeks | |
Secondary | Muscle strength | Muscle strength will be assessed by the one-repetition maximum test on the bench press and knee extension machines and will be expressed as kilograms. | Change from baseline to 12 weeks | |
Secondary | Muscle strength | Muscle strength will be assessed by the one-repetition maximum test on the bench press and knee extension machines and will be expressed as kilograms. | Change from baseline to 24 weeks | |
Secondary | Handgrip strength | Handgrip strength will be assessed using handgrip dynamometry and expressed as kilograms. | Change from baseline to 12 weeks | |
Secondary | Handgrip strength | Handgrip strength will be assessed using handgrip dynamometry and expressed as kilograms. | Change from baseline to 24 weeks | |
Secondary | Functional capacity - Timed-Stands | Functional capacity will be assessed using the "Timed-Stands" test and expressed by the number of sit-to-stand repetitions. | Change from baseline to 12 weeks | |
Secondary | Functional capacity - Timed-Stands | Functional capacity will be assessed using the "Timed-Stands" test and expressed by the number of sit-to-stand repetitions. | Change from baseline to 24 weeks | |
Secondary | Functional capacity - Timed Up-And-Go | Functional capacity will be assessed busing the "Timed Up-And-Go" test and expressed in seconds. | Change from baseline to 12 weeks | |
Secondary | Functional capacity - Timed Up-And-Go | Functional capacity will be assessed busing the "Timed Up-And-Go" test and expressed in seconds. | Change from baseline to 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02776735 -
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
|
Phase 2 | |
Active, not recruiting |
NCT03092427 -
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
|
N/A | |
Not yet recruiting |
NCT05545098 -
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
|
||
Not yet recruiting |
NCT03833609 -
Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT02524340 -
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
|
||
Recruiting |
NCT01434082 -
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT04671524 -
The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected
|
N/A | |
Recruiting |
NCT04167488 -
Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
|
N/A | |
Recruiting |
NCT04205500 -
Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis
|
N/A | |
Terminated |
NCT01694264 -
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
|
Phase 3 | |
Completed |
NCT02824978 -
Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
|
||
Active, not recruiting |
NCT03841357 -
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
|
Phase 3 | |
Completed |
NCT03833271 -
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
|
Early Phase 1 | |
Completed |
NCT01455701 -
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 1 | |
Completed |
NCT05031104 -
Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis
|
N/A | |
Not yet recruiting |
NCT01436019 -
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
|
N/A | |
Recruiting |
NCT05609630 -
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
|
Phase 3 | |
Recruiting |
NCT05696340 -
Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
|
||
Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
Completed |
NCT05436301 -
Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)
|